FORM	4
------	---

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Response	es)										
1. Name and Address of Szakacs Cameron	2. Issuer Name <b>an</b> Cellectar Bioscie			0.2	ol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last)       (First)       (Middle)         C/O CELLECTAR BIOSCIENCES, INC., 3301       3. Date of Earliest Transaction (Month/Day/Year)         11/24/2014       11/24/2014								X Officer (give title below) Other (specify below) VP of Clinical Development			
MADISON, WI 537		4. If Amendment, D	ate Original	l Fileo	d(Month/Da	y/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security		2. Transaction	2A. Deemed	3. Transaction		4. Secur	4. Securities Acquired		5. Amount of Securities Beneficially	6.	7. Nature
(Instr. 3)		Date (Month/Day/Year)				(A) or Disposed of (D) (Instr. 3, 4 and 5)			Owned Following Reported Transaction(s)	Ownership Form:	of Indirect Beneficial
			(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information SEC 1474 (9-02) contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)															
Derivative Security (Instr. 3)	Price of	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	TransactionofCodeDerivative(Instr. 8)Securities		Expiration Date (Month/Day/Year)		Amount of Underlying Securities		Derivative Security (Instr. 5)	Securities Beneficially	Ownership Form of Derivative	Beneficial Ownership		
	Derivative Security					Acquired (A) or Disposed (D) (Instr. 3, and 5)	or posed of tr. 3, 4,		(Instr. 3 and 4)			Following Reported Transaction(s)	Direct (D) or Indirect	(Instr. 4)	
				Code	v	(A)		Exercisable	Expiration Date	Title	Amount or Number of Shares				
Employee Stock Option (right to buy)	\$ 2.74	11/24/2014		А		50,000		<u>(1)</u>	11/24/2024	Common Stock	50,000	\$ 0	50,000	D	

## **Reporting Owners**

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Szakacs Cameron C/O CELLECTAR BIOSCIENCES, INC. 3301 AGRICULTURE DRIVE MADISON, WI 53716			VP of Clinical Development					

## Signatures

 /s/ Chad Kolean, attorney-in-fact for Cameron Szakacs
 12/18/2014

 Signature of Reporting Person
 Date

# **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Option vests in equal quarterly increments over a period of three years from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.